Healthcare Industry News: heart failure
News Release - February 13, 2015
Horizon Pharma plc Submits Investigational New Drug Application for ACTIMMUNE(R) in the Treatment of Friedreich's AtaxiaPhase 3 Study Expected to Begin in Q2 2015
DUBLIN, IRELAND--(Healthcare Sales & Marketing Network) - Horizon Pharma plc (HZNP), a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs, today announced it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for ACTIMMUNE in the treatment of Friedreich's Ataxia (FA). The Company has simultaneously requested Fast Track Designation.
The Company plans to begin a Phase 3 study in the second quarter in collaboration with the Friedreich's Ataxia Research Alliance (FARA) and the investigators and clinics of FARA's Collaborative Clinical Research Network (CCRN) in FA.
"This is a significant step forward in the further development of ACTIMMUNE beyond the approved indications of chronic granulomatous disease and severe, malignant osteopetrosis," said Timothy P. Walbert, chairman, president and chief executive officer, Horizon Pharma plc. "We have established a successful partnership with the Friedreich's Ataxia Research Alliance and its Collaborative Clinical Research Network in Friedreich's Ataxia and look forward to working with them on this study in order to potentially bring a treatment option to the estimated 3,700 people in the United States with this devastating disease."
The Phase 3 study is expected to be a randomized, double-blind, multicenter, placebo-controlled, 26-week study evaluating ACTIMMUNE in approximately 90 male and non-pregnant female subjects between the ages of 10 and 25 years, inclusive, with an FA functional stage of greater than 1 to less than 5 and the ability to walk 25 feet with or without an assistive device. Subjects will be randomized 1:1 to receive either ACTIMMUNE or matching placebo. The primary endpoint will be the change in the Friedreich's Ataxia Rating Scale-modified neurological exam score (FARS-mNeuro), which is a measure of disease activity and correlates significantly with functional disability, from baseline to 26 weeks for patients treated with ACTIMMUNE compared to placebo. It is anticipated that it will take 18 months to completely enroll the study. A six-month open-label extension study will be offered to those FA patients completing the Phase 3 study.
"We are greatly encouraged by the collaborative efforts of the FDA, Horizon Pharma and all concerned to find a potential treatment option for FA," said Ronald Bartek, president and co-founder of FARA. "Our registry of FA patients will play an important role in identifying subjects for the study. We currently have more than 2,400 FA patients in our registry and are pleased to work together with Horizon Pharma to further our knowledge of ACTIMMUNE as a potential treatment of FA."
About Friedreich's Ataxia (FA)
FA is a debilitating, life-shortening and degenerative neuro-muscular disorder that affects about one in 50,000 people in the United States. Onset of symptoms can vary from five years old to adulthood, with the childhood onset tending to be associated with a more rapid progression. A progressive loss of coordination and muscle strength leads to motor incapacitation and often the full-time use of a wheelchair. Most young people diagnosed with FA require mobility aids such as a cane, walker or wheelchair by their teens or early 20's. There are currently no approved treatments for FA. For more information about FA, visit the Friedreich's Ataxia Research Alliance (FARA) website at www.curefa.org.
ACTIMMUNE (interferon gamma-1b) is a biologically manufactured protein similar to one the body makes naturally to help prevent infection. ACTIMMUNE is currently approved by the U.S. Food and Drug Administration (FDA) for use in two rare diseases. It is indicated to reduce the frequency and severity of serious infections associated with Chronic Granulomatous Disease (CGD), a genetic disorder that affects the functioning of some cells of the immune system. In addition, ACTIMMUNE is indicated to slow the worsening of severe, malignant osteopetrosis (SMO), a genetic disorder that affects normal bone formation. For more information, please see www.ACTIMMUNE.com.
IMPORTANT SAFETY INFORMATION
APPROVED USES FOR ACTIMMUNE (interferon gamma 1-b)
Chronic Granulomatous Disease (CGD)
ACTIMMUNE is indicated to reduce the frequency and severity of serious infections associated with Chronic Granulomatous Disease. CGD is a genetic disorder that affects the functioning of some cells of the immune system.
Severe, Malignant Osteopetrosis (SMO)
ACTIMMUNE is indicated to slow the worsening of severe, malignant osteopetrosis. SMO is a genetic disorder that affects normal bone formation.
IMPORTANT SAFETY INFORMATION (ISI)
The most common side effects with ACTIMMUNE are "flu-like" symptoms such as fever, headache, chills, myalgia (muscle pain) or fatigue, which may decrease in severity as treatment continues. Bedtime administration of ACTIMMUNE may minimize some of these symptoms. Acetaminophen may be helpful in preventing fever and headache.
If you are pregnant or plan to become pregnant or plan to nurse you should consult your physician.
ACTIMMUNE can cause severe allergic reactions and/or rash. Do not use ACTIMMUNE if you are allergic to interferon-gamma, E. coli-derived products or any component of the product (See Full Prescribing Information for a list of components). If you develop a serious reaction to ACTIMMUNE, discontinue it immediately and contact your doctor or seek medical help.
At high doses, ACTIMMUNE can cause (flu-like) symptoms, which may worsen some pre-existing heart conditions. Tell your doctor if you have a cardiac condition, such as irregular heartbeat, heart failure or decreased blood flow to your heart.
ACTIMMUNE may cause reversible changes to your nervous system, including decreased mental status, walking disturbances and dizziness. Tell your doctor if you have a history of seizures or other neurologic disorders.
Bone marrow function may be suppressed with ACTIMMUNE and decreased production of cells important to the body may occur. This effect, which can be severe, is usually reversible when the drug is discontinued or the dose is reduced. Tell your doctor if you have, or have had, reduced bone marrow function. Your doctor will monitor these cells with blood tests at the beginning of therapy and at 3 month intervals thereafter.
Taking ACTIMMUNE may cause reversible changes to your liver function, particularly in patients less than one year old. Your doctor will monitor your liver function with blood tests at the beginning of therapy and at 3 month intervals. If the patient is 1 year or less, monitoring will be done on a monthly basis.
If you are receiving ACTIMMUNE at home, your doctor will provide to you or your caregiver appropriate instructions on the administration of the drug and disposal of the container, needles and syringes.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
This information is not intended to replace discussions with your doctor. For additional information about ACTIMMUNE, please consult the Full Prescribing Information and the Information for the Patient/Caregiver and talk to your doctor. ACTIMMUNE is available by prescription only.
Visit www.ACTIMMUNE.com to download a copy of the ACTIMMUNE Full Prescribing Information.
About Horizon Pharma plc
Horizon Pharma plc is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs. The company markets a portfolio of products in arthritis, inflammation and orphan diseases. The company's U.S. marketed products are ACTIMMUNE® (interferon gamma-1b), DUEXIS® (ibuprofen/famotidine), PENNSAID® (diclofenac sodium topical solution) 2% w/w, RAYOS® (prednisone) delayed-release tablets and VIMOVO® (naproxen/esomeprazole magnesium). Horizon's global headquarters are in Dublin, Ireland. For more information, please visit www.horizonpharma.com.
This press release contains forward-looking statements, including statements regarding the design and timing of Horizon's planned Phase 3 clinical trial of ACTIMMUNE in FA, the potential for ACTIMMUNE as a treatment for FA patients and future collaborative efforts between Horizon and FARA and the CCRN in FA. Forward-looking statements speak only as of the date of this press release and Horizon does not undertake any obligation to update or revise these statements, except as may be required by law. These forward-looking statements are based on management's expectations and assumptions as of the date of this press release and actual results may differ materially from those in these forward-looking statements as a result of various factors. These factors include, but are not limited to, risks regarding whether results of subsequent studies will be consistent with results of the Phase 2 clinical trial of ACTIMMINE in FA, Horizon's ability to identify and enroll patients in the planned Phase 3 study, potential delays in initiating and completing the planned Phase 3 study and whether and when the FDA allows the IND. For a further description of these and other risks facing Horizon, please see the risk factors described in Horizon's filings with the United States Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in those filings. Forward-looking statements speak only as of the date of this press release and Horizon undertakes no obligation to update or revise these statements, except as may be required by law.
Source: Horizon Pharma
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.